Filter your results
- 1
- 1
- 1
- 1
- 2
- 1
- 1
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
TP53, XPO1 and ATM Mutations Exclusive Distribution in the Adverse Prognosis Chronic Lymphocytic Leukemia (CLL) GroupSOHO, Sep 2018, Houston (Texas), United States. 18, pp.S218, 2018, ⟨10.1016/j.clml.2018.07.084⟩
Conference poster
inserm-03950185v1
|
||
|
TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemiaAmerican Journal of Hematology, 2022, 97 (4), pp.E159-E162. ⟨10.1002/ajh.26479⟩
Journal articles
hal-03557401v1
|